클로미프라민
Clomipramine
Clomipramine HCl
다른 이름: Clomicalm · Anafranil · clomipramini hydrochloridum · G-34586 · monochlorimipramine hydrochloride · Clofranil · Clopram · Clopress · Equinorm · Hydiphen · Maronil · Novo-Clopamine · Placil · Tranquax · Zoiral · Clomipraminum · Clomipramine hydrochloride
VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
동물 종별 용량
🌎 NA — North America🌍 EU — Europe
개
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Label directions (Clomicalm) | 2-4 mg/kg | PO | once daily or divided twice daily | — | 🌎 NA |
| Behavioral disorders | 3 mg/kg | PO | q12h | — | 🌎 NA |
| Male dimorphic behaviors, fearful/fear aggression, noise phobias, obsessive/compulsive behaviors | 1 mg/kg PO every 12 hours for 2 weeks; then 2 mg/kg PO q12h for 2 weeks, then 3 mg/kg PO q12h for 4 weeks and maintain | PO | q12h | Maintain after 8 weeks | 🌎 NA |
| Adjunctive treatment of storm phobia | Clomipramine 2 mg/kg PO q12h for 3 months, then 1 mg/kg PO q12h, then 0.5 mg/kg PO q12h for 2 weeks | PO | q12h | 3.5 months | 🌎 NA |
| Separation-related disorders, anxiety, compulsive behaviors, noise fears, cataplexy | 1-2 mg/kg | PO | q12h | Long-term (e.g., 3 months for cataplexy) | 🌍 EU |
- Behavioral disorders: start at a low dose (e.g., 1 mg/kg for 2 weeks, then 2 mg/kg for 2 weeks, then 3 mg/kg)
- Male dimorphic behaviors, fearful/fear aggression, noise phobias, obsessive/compulsive behaviors: May take 4-6 weeks to see apparent improvement.
- Adjunctive treatment of storm phobia: Used with alprazolam (0.02 mg/kg PO as needed 1 hour before anticipated storms and q4h as needed) and behavior modification
- Separation-related disorders, anxiety, compulsive behaviors, noise fears, cataplexy: Licensed for use in association with a behaviour modification plan for separation-related disorders.
고양이
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Urine marking/spraying; inter-cat aggression; redirected aggression; compulsive grooming/wool sucking | 0.5 mg/kg | PO | once daily | — | 🌎 NA |
| Behavioral disorders | 0.3-0.5 mg/kg | PO | q24h | — | 🌎 NA |
| Behavioral disorders | 0.5-1 mg/kg | PO | once daily | — | 🌎 NA |
| Urine marking | 0.3-0.5 mg/kg PO q24h (2.5-5 mg per cat q24h) | PO | q24h | — | 🌎 NA |
| Anxiety-related disorders, compulsive behaviours, urine spraying | 0.25-1 mg/kg | PO | q24h | — | 🌍 EU |
- Anxiety-related disorders, compulsive behaviours, urine spraying: Monitor for urinary retention.
새
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Adjunctive treatment of feather picking | 0.5-9 mg/kg | PO | q12-24h | — | 🌎 NA |
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
개요
클로미프라민은 주로 수의 행동 의학에서 사용되는 삼환계 항우울제(TCA)입니다.
- 개: 강박 장애(의식적인 상동 행동) 및 분리 불안 치료제로 FDA 승인을 받았습니다. 우위성 공격성 및 소음 공포증에도 오프라벨로 사용됩니다.
- 고양이: 소변 스프레이, 심인성 탈모, 강박적 그루밍과 같은 행동 문제에 오프라벨로 사용됩니다.
- 조류: 깃털 뽑기 행동을 치료하는 데 사용됩니다.
임상 팁: 대부분의 TCA 및 SSRI와 마찬가지로 최대의 임상적 효과를 관찰하기 위해서는 장기간(보통 4~8주)의 치료가 필요합니다. 단독 치료보다는 포괄적인 행동 교정 계획의 보조 수단으로 사용하는 것이 이상적입니다.
작용 기전
The exact mechanism of action of tricyclic antidepressants involves the blockade of monoamine reuptake in the central nervous system.
- Primary Action: Clomipramine predominantly inhibits the presynaptic reuptake of serotonin (5-HT) via the serotonin transporter (SERT) → increasing synaptic serotonin concentrations.
- Active Metabolite: Its primary active metabolite, desmethylclomipramine, primarily inhibits the reuptake of norepinephrine (NE) via the norepinephrine transporter (NET).
- Receptor Downregulation: The chronic elevation of these neurotransmitters leads to the gradual down-regulation of post-synaptic receptors, which correlates with the delayed onset of clinical behavioral effects (taking several weeks).
- Off-target Effects: TCAs also exhibit antagonism at muscarinic (cholinergic), histamine (H1), and alpha-1 adrenergic receptors, which are responsible for many of their adverse effects (e.g., dry mouth, sedation, hypotension).
안전성·주의사항
금기사항
- Prior hypersensitivity to clomipramine or other tricyclic antidepressants
- Concomitant use with monoamine oxidase inhibitors (MAOIs) within 14 days
- Concurrent ingestion of aged cheeses (high tyramine content)
- Known sensitivity to tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs)
- Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) or within 2 weeks of their use
- Male breeding animals (due to risk of testicular hypoplasia)
부작용
- Emesis
- Diarrhea
- Sedation, lethargy, and depression
- Anticholinergic effects (dry mouth, tachycardia, urinary retention)
- Elevation of liver enzymes
- Pancreatitis (rarely reported in dogs)
- Birds: Ataxia, drowsiness, regurgitation
- Sporadic vomiting
- Changes in appetite
- Urinary retention (especially in cats)
- Testicular hypoplasia (in male breeding animals)
주의
Seizure Warning: TCAs may lower the seizure threshold. Use with extreme caution in animals with preexisting seizure disorders.
- Anticholinergic Risks: Use cautiously in patients with decreased GI motility, urinary retention, cardiac rhythm disturbances, or increased intraocular pressure.
- Hepatic Function: May cause hepatic abnormalities. Baseline and annual monitoring of liver enzymes is recommended for long-term use.
- Thyroid Disease: Use cautiously in hyperthyroid patients or those on thyroid supplementation due to increased risk of cardiac arrhythmias.
- Reproductive Safety: Not a known teratogen, but high doses have demonstrated testicular atrophy. The manufacturer warns against use in breeding male dogs. FDA Category C for human pregnancy.
- Species Sensitivity: Cats may be more sensitive to adverse effects (sedation, anticholinergic signs) due to slower elimination of the desmethyl metabolite.
약물 상호작용
Additive anticholinergic effects; use cautiously
Risk of extrapyramidal side effects (reported in a macaw)
May inhibit tricyclic antidepressant metabolism and increase the risk of toxicity
Increased risk for prolonged QT interval
May cause increased blood pressure
Additive CNS depression; use cautiously
Increased risk for serotonin syndrome
Increased risk for QTc interval prolongation and tricyclic adverse effects
May decrease tricyclic blood levels
Increased risk for serotonin syndrome
May increase the risk of cardiac effects (arrhythmias, hypertension, hyperpyrexia)
Concomitant use is generally contraindicated due to high risk of fatal serotonin syndrome
Risk of fatal serotonin syndrome; do not use concurrently or within 2 weeks of each other
Potentiation of anticholinergic effects (e.g., dry mouth, tachycardia, urinary retention)
Potentiation of CNS depressant effects
Potentiation of CNS depressant effects (though noted as safe to use together with care)
Potentiation of sympathomimetic cardiovascular effects
Potentiation of anticoagulant effects
Increased plasma levels of the antiepileptic drug
Increased plasma levels of the antiepileptic drug
Increased risk of serotonin syndrome; use only in exceptional cases with careful monitoring
High risk of fatal serotonin syndrome. Do not use within 2 weeks of each other.
Increased risk of serotonin syndrome. Use with trazodone only in exceptional cases with careful monitoring.
May potentiate anticholinergic effects.
May potentiate CNS depressant effects.
May potentiate sympathomimetic effects.
Plasma levels of the antiepileptic drugs may be increased by co-administration.
모니터링
- Clinical efficacy (behavioral improvement)
- Baseline and annual liver function tests
- EKG (especially in patients with cardiac risks or hyperthyroidism)
- Clinical efficacy (reduction in anxiety/compulsive behaviors)
- Signs of serotonin syndrome (agitation, tremors, hyperthermia, tachycardia) if used with other serotonergic drugs
- Urinary output and frequency, particularly in cats
- Appetite and gastrointestinal tolerance
약동학
반감기
흡수
Dogs: Rapidly converted in the liver to active metabolite desmethylclomipramine. Food decreases AUC for the parent compound by ~25% but not the metabolite. Cats: Oral bioavailability averages 90%. Humans: Well absorbed but substantial first-pass effect reduces systemic bioavailability to ~50%.
분포
Highly lipophilic and widely distributed throughout the body (Vd = 17 L/kg). Highly bound to plasma proteins (96%). Crosses the placenta, maternal milk, and the blood-brain barrier.
대사
Metabolized principally in the liver to several metabolites, including the active desmethylclomipramine. Cats metabolize clomipramine more slowly than dogs (male cats slower than females).
배설
About two-thirds of metabolites are eliminated in the urine and the rest in the feces.
과다투여
Clomipramine has a narrow margin of safety. Significant clinical signs can be seen at or slightly above the therapeutic range (2-3 mg/kg).
- Lethal Dose: In dogs, lethal doses are approximately 50-100 mg/kg/day PO (12.5-25X recommended dose).
- Clinical Signs (Dogs): Lethargy, tachycardia, ataxia, depression, vocalization, and vomiting.
- Clinical Signs (Cats): Lethargy, mydriasis, tachypnea, ataxia, depression, and tachycardia.
- Severe Toxicity: Overdosage with TCAs can be life-threatening, leading to severe arrhythmias, seizures, and cardiorespiratory collapse.
Action: Because toxicities and therapies are complicated and controversial, contact an animal poison control center immediately in any potential overdose situation.
제품
제형
- Oral tablets
- Oral capsules
- 5 mg tablet
- 20 mg tablet
- 80 mg tablet
동물용의약품
- Clomipramine HCl Oral Tablets: 5 mg, 20 mg, 40 mg, & 80 mg (Clomicalm®)
- Clomicalm 5 mg tablets
- Clomicalm 20 mg tablets
- Clomicalm 80 mg tablets
인용의약품
- Clomipramine Oral Capsules: 25 mg, 50 mg, & 75 mg (Anafranil®)
- Anafranil 10 mg, 25 mg, 50 mg, 75 mg capsules/tablets
규제 현황
Licensed for separation-related disorders in dogs.
POM-V classification.
규제 데이터 없음: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
보관·안정성
Veterinary tablets should be stored in a dry place at controlled room temperature (15-30°C) in the original closed container. Human capsules should be stored at <30°C in tight containers and protected from moisture.
보호자 정보
- 인내심이 필요합니다: 반려동물의 행동에 긍정적인 효과가 나타나기까지 몇 주(보통 4~8주)가 걸릴 수 있습니다.
- 훈련 병행: 수의사 또는 수의 행동 전문가가 제공하는 행동 교정 계획과 병행할 때 가장 효과적입니다.
- 투여 방법: 음식과 함께 또는 빈속에 투여할 수 있습니다. 약물 복용 후 구토를 한다면 식사와 함께 투여해 보십시오.
- 갑자기 중단하지 마십시오: 수의사의 지시 없이 갑자기 치료를 중단하지 마십시오. 금단 증상이나 행동 재발을 유발할 수 있습니다.
- 독성 경고: 이 약은 반려동물과 어린이의 손이 닿지 않는 곳에 엄격히 보관하십시오. 과다 복용 시 매우 치명적일 수 있습니다.
VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.